Literature DB >> 20955882

Surgical and nonresectional therapies for pulmonary metastasis.

Yifan Zheng1, Hiran C Fernando.   

Abstract

Resection of pulmonary metastases is reasonable and is commonly performed for patients whose primary disease is controlled and for whom the metastatic burden in the chest is such that all disease can be resected safely. The use of video- assisted thoracic surgery rather than an open approach in metastasectomy, however, is still being debated. In addition, nonresectional therapies such as radiofrequency ablation and stereotactic body radiation therapy are being used in centers for patients with oligometastases to the lungs. This article reviews the indications and approaches for surgical resection, as well as these other nonresectional therapies. At present, it is difficult to directly compare these approaches because of the heterogeneous nature of metastasectomy series. Moreover, the stereotactic body radiation therapy and radiofrequency ablation studies have involved smaller numbers of patients and shorter follow-up than the surgical studies. The preliminary data for these nonresectional therapies, however, are encouraging and certainly should be considered in the decision tree when treating patients with pulmonary metastases.
Copyright © 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20955882     DOI: 10.1016/j.suc.2010.06.003

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  9 in total

Review 1.  Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG).

Authors: 
Journal:  Ann Oncol       Date:  2018-04-01       Impact factor: 32.976

2.  Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis.

Authors:  Yang Yang; Jun Li; Feng Liu; Leaf Huang
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

3.  Nanotechnology for cancer treatment.

Authors:  William H Gmeiner; Supratim Ghosh
Journal:  Nanotechnol Rev       Date:  2015-04       Impact factor: 7.848

4.  Impact of resection margin length and tumor depth on the local recurrence after thoracoscopic pulmonary wedge resection of a single colorectal metastasis.

Authors:  Jae Ho Chung; Sung Ho Lee; Eunjue Yi; Ju Yong Lim; Jae Seung Jung; Ho Sung Son; Kyung Sun
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

5.  Generation and evaluation of a monoclonal antibody, designated MAdL, as a new specific marker for adenocarcinomas of the lung.

Authors:  H Schultz; S Marwitz; B Baron-Lühr; G Zissel; C Kugler; K F Rabe; P Zabel; E Vollmer; J Gerdes; T Goldmann
Journal:  Br J Cancer       Date:  2011-08-02       Impact factor: 7.640

6.  Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases.

Authors:  T de Baère; A Aupérin; F Deschamps; P Chevallier; Y Gaubert; V Boige; M Fonck; B Escudier; J Palussiére
Journal:  Ann Oncol       Date:  2015-02-16       Impact factor: 32.976

7.  Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastases.

Authors:  Valerie Kedinger; Aline Meulle; Omar Zounib; Marie-Elise Bonnet; Jean-Baptiste Gossart; Elodie Benoit; Melanie Messmer; Pattabhiraman Shankaranarayanan; Jean-Paul Behr; Patrick Erbacher; Anne-Laure Bolcato-Bellemin
Journal:  BMC Cancer       Date:  2013-07-09       Impact factor: 4.430

8.  [The diagnosis and surgical treatment for solitary pulmonary metastases: a report of 156 cases].

Authors:  Hui Zhang; Xiaofeng Chen; Haibing Wang; Lei Zhang; Wenyong Zhou; Mingchuan Zhao
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2012-04

Review 9.  Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers.

Authors:  Md Emranul Karim; Kyi Kyi Tha; Iekhsan Othman; Mohammad Borhan Uddin; Ezharul Hoque Chowdhury
Journal:  Pharmaceutics       Date:  2018-05-26       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.